계명대학교 의학도서관 Repository

Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer

Metadata Downloads
Author(s)
Ho Il YoonOh-Ran KwonKyung Nam KangYong Sung ShinHo Sang ShinEun Hee YeonKeon Young KwonIlseon HwangYoon Kyung JeonYongdai KimChul Woo Kim
Keimyung Author(s)
Hwang, Il SeonKwon, Kun Young
Department
Dept. of Pathology (병리학)
Journal Title
Journal of Cancer Prevention
Issued Date
2016
Volume
21
Issue
3
Keyword
Lung neoplasmsBiomarkers
Abstract
Background: Despite major advances in lung cancer treatment, early detection remains the most promising way of improving outcomes.
To detect lung cancer in earlier stages, many serum biomarkers have been tested. Unfortunately, no single biomarker can reliably detect
lung cancer. We combined a set of 2 tumor markers and 4 inflammatory or metabolic markers and tried to validate the diagnostic
performance in lung cancer.
Methods: We collected serum samples from 355 lung cancer patients and 590 control subjects and divided them into training and
validation datasets. After measuring serum levels of 6 biomarkers (human epididymis secretory protein 4 [HE4], carcinoembryonic antigen
[CEA], regulated on activation, normal T cell expressed and secreted [RANTES], apolipoprotein A2 [ApoA2], transthyretin [TTR], and
secretory vascular cell adhesion molecule-1 [sVCAM-1]), we tested various sets of biomarkers for their diagnostic performance in lung
cancer.
Results: In a training dataset, the area under the curve (AUC) values were 0.821 for HE4, 0.753 for CEA, 0.858 for RANTES, 0.867
for ApoA2, 0.830 for TTR, and 0.552 for sVCAM-1. A model using all 6 biomarkers and age yielded an AUC value of 0.986 and sensitivity
of 93.2% (cutoff at specificity 94%). Applying this model to the validation dataset showed similar results. The AUC value of the model
was 0.988, with sensitivity of 93.33% and specificity of 92.00% at the same cutoff point used in the validation dataset. Analyses by
stages and histologic subtypes all yielded similar results.
Conclusions: Combining multiple tumor and systemic inflammatory markers proved to be a valid strategy in the diagnosis of lung cancer.
Keimyung Author(s)(Kor)
황일선
권건영
Publisher
School of Medicine
Citation
Ho Il Yoon et al. (2016). Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer. Journal of Cancer Prevention, 21(3), 187–193. doi: 10.15430/JCP.2016.21.3.187
Type
Article
ISSN
2288-3649
DOI
10.15430/JCP.2016.21.3.187
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32622
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Pathology (병리학)
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.